
The turn of the year marked Lars Fruergaard Jørgensen's fourth year in charge of Novo Nordisk, and even though the 54-year-old president and CEO has no plans to leave his post any time soon, a lot of his energy goes into cementing the legacy which he will one day pass on to his successor.
"This is actually what I spend most of my time on," says Fruergaard Jørgensen in conversation with MedWatch.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app